A federal jury has ordered Apple Inc. to pay medical technology firm Masimo $634 million in damages, concluding that the tech giant infringed on proprietary pulse oximetry patents. The verdict marks a pivotal escalation in the long-standing legal warfare over the blood oxygen monitoring technology integrated into the Apple Watch, reinforcing Masimo’s claims of intellectual property theft.
Ongoing Regulatory Disputes and Import Challenges
The legal conflict continues to ripple through federal agencies and international trade channels. Masimo is currently suing U.S. Customs and Border Protection, contesting the agency’s decision to allow the importation of Apple Watch models equipped with a modified blood oxygen implementation. In a parallel effort to regain market momentum, Apple has asked an appeals court to formally overturn the import ban that has restricted its flagship wearable devices.
Apple’s Symbolic Countersuit Victory
Despite the massive financial penalty regarding technical patents, Apple secured a minor legal win in its countersuit against Masimo. A jury determined that Masimo violated specific Apple design patents, though the court awarded Apple only the statutory minimum payment of $250. This stark contrast in damages highlights the high stakes of functional utility patents compared to aesthetic design protections in the wearable technology sector.
